AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- The University of Pennsylvania will enrol patients in the Phase 1/2 multi-centre clinical trial for the CHM CDH17 cell therapy.
- This study aims to determine the optimal Phase 2 dosage of CHM CDH17 and evaluate its safety and efficacy.
- In August 2024, CHM announced the enrolment of the first patient for this clinical trial.
- Additional clinical trial sites are expected to start enrolling participants in the second half of 2024.
Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced positive developments regarding its CHM CDH17 cell therapy. World-renowned cell therapy centre, the University of Pennsylvania is now enrolling patients in the Phase 1/2 multi-centre clinical trial for this therapy.
This two-stage study aims to determine the optimal Phase 2 dosage of CHM CDH17 and assess its safety and efficacy in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours.
On 28 August 2024, CHM announced the enrolment of the first patient in this clinical trial.
Image source: Company update
Reflecting on the development, Jennifer Eads, MD, the study’s principal investigator from the University of Pennsylvania, said, “After over a decade of development here at Penn, it is thrilling to be advancing CHM CDH17 as a potential new medicine for cancer patients.”
Additional clinical trial sites are expected to begin enrolling participants in the latter half of 2024.
Chimeric Therapeutics currently has a diversified portfolio, including first-in-class autologous CAR T cell therapies and best-in-class allogeneic NK cell therapies. Its assets are being developed across multiple oncology-related disease areas. The company has three clinical-stage programs.
CHM shares trade higher
CHM shares saw a rise of over 6.6%, trading at AU$0.016, at the time of writing on 11 September 2024.
